Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

June 22, 2020June 22, 2020

Pre-Surgical Imfinzi Combo Increases Cancer Eradication Chances in Trial

News

Treating high-risk, HER2-negative breast cancer patients before surgery with the immunotherapy Imfinzi (durvalumab) plus Lynparza (olaparib) and chemotherapy increases the probability for complete cancer eradication, according to the results from a ... Read more

April 23, 2020April 23, 2020

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

News

The U.S. Food and Drug Administration (FDA) has approved Immunomedics’ antibody-drug conjugate Trodelvy (sacituzumab govitecan) to treat triple-negative breast cancer (TNBC) patients who already tried at least two previous therapies for metastatic ... Read more

March 13, 2020March 13, 2020

Platinum Chemo No Better than Standard in BRCA-mutated Early BC, Trial Finds

News

Women with newly diagnosed breast cancer who carry a mutation in their BRCA genes may continue to receive the standard pre-surgery chemotherapy regimen used for other breast cancer patients, ... Read more

February 24, 2020March 5, 2020

Magseed Approval Extended in Europe for Soft Tissues, Long-Term Implantation

News

Magseed, a small magnetic marker by Endomag designed to accurately mark the site of cancer cells before surgery, is now approved in Europe for use in any soft tissue ... Read more

January 20, 2020January 20, 2020

Leronlimab Combo Shows Promise for Metastatic TNBC in Early Phase 1b/2 Trial Data

News

Investigational therapy leronlimab is showing promise as a potential therapy for people with CCR5-positive metastatic triple-negative breast cancer (mTNBC), early data from a Phase 1b/2 clinical trial suggest. The ... Read more

January 10, 2020January 10, 2020

Keytruda, Imprime PGG Combo Increases Overall Survival in Metastatic Triple-negative BC, Data Show

News

Treatment with Biothera Pharmaceutical‘s Imprime PGG appears to increase the sensitivity of chemotherapy-resistant metastatic triple-negative breast cancers (mTNBC) to the immune checkpoint inhibitor Keytruda (pembrolizumab), interim data from a Phase 2 ... Read more

December 17, 2019January 15, 2020

Dosing Complete in Phase 2 Trial Evaluating Lymfactin for BC Treatment-Associated Lymphedema

News

Herantis Pharma has completed patient dosing in its Phase 2 trial evaluating the investigational gene therapy Lymfactin for secondary lymphedema — a common complication of breast cancer treatment caused ... Read more

November 11, 2019November 11, 2019

Blood Test May Identify Breast Cancer Years Before Symptoms Appear, Pilot Study Suggests

News

A simple blood test – which measures antibodies against certain tumor proteins, or antigens — may identify breast cancer up to five years before clinical signs of cancer are ... Read more

September 16, 2019

TNBC Patient Given Investigative Antibody, Leronlimab, Under Emergency Exception

News

A metastatic triple-negative breast cancer (TNBC) patient is being treated with CytoDyn’s investigational leronlimab (PRO 140) under an emergency investigational new drug (IND) application granted by the U.S. Food ... Read more

September 13, 2019September 13, 2019

FDA to Review Nerlynx Combo as Third-line Treatment for HER2-positive Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has agreed to review Puma Biotechnology’s application seeking approval of Nerlynx (neratinib), in combination with capecitabine, to treat HER2-positive breast cancer patients with metastatic disease, ... Read more

Pin It on Pinterest